Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
Joint Authors
Zheng, Peng
Liang, Chunmin
Ren, Li
Zhu, Dexiang
Feng, Qingyang
Chang, Wenju
He, Guodong
Ye, Lechi
Chen, Jingwen
Lin, Qi
Yi, Tuo
Ji, Meiling
Niu, Zhengchuan
Jian, Mi
Wei, Ye
Xu, Jianmin
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-16
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
Purpose.
We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
Methods.
The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuximab.
Next-generation sequencing was done for single nucleotide polymorphism according to custom panel.
Potential predictive biomarkers were identified and integrated into a predictive model within a training cohort.
The model was validated in a validation cohort.
Results.
Thirty-one of 247(12.6%) patients harbored RAS mutations.
In training cohort (N=93), six potential predictive genes, namely, ATP6V1B1, CUL9, ERBB2, LY6G6D, PTCH1, and RBMXL3, were identified.
According to predictive model, patients were divided into responsive group (n=66) or refractory group (n=27).
In responsive group, efficacy outcomes were significantly improved by addition of cetuximab to chemotherapy.
In refractory group, no benefit was observed.
Interaction test was significant across all endpoints.
In validation cohort (N=123), similar results were also observed.
Conclusions.
In the first-line treatment of mCRC, the predictive model integrating six new predictive mutations divided patients well, indicating a promising approach to further refine patient selection for cetuximab on the basis of RAS mutations.
American Psychological Association (APA)
Zheng, Peng& Liang, Chunmin& Ren, Li& Zhu, Dexiang& Feng, Qingyang& Chang, Wenju…[et al.]. 2018. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology،Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
Modern Language Association (MLA)
Zheng, Peng…[et al.]. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology No. 2018 (2018), pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
American Medical Association (AMA)
Zheng, Peng& Liang, Chunmin& Ren, Li& Zhu, Dexiang& Feng, Qingyang& Chang, Wenju…[et al.]. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology. 2018. Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1195803